DURHAM, N.C., July 23, 2026
Atsena Therapeutics announced that the European Medicines Agency (EMA) has granted Orphan Designation to its two clinical-stage gene therapy candidates, ATSN-101 for Leber Congenital Amaurosis Type 1 (LCA1) and ATSN-201 for X-linked Retinoschisis (XLRS). The designation marks an important regulatory milestone for the company’s inherited retinal disease pipeline, providing significant development incentives including reduced regulatory fees, clinical protocol assistance, research support, and up to 10 years of market exclusivity in the European Union following approval. The recognition comes as ATSN-201 continues enrollment in its global pivotal Phase 3 LIGHTHOUSE trial, while ATSN-101 is scheduled to enter a global Phase 3 clinical trial later this year. Atsena believes these programs have the potential to address significant unmet medical needs for patients affected by rare inherited retinal disorders that currently have no approved disease-modifying therapies, reinforcing the company’s mission to develop genetic medicines capable of reversing or preventing blindness.
EMA Recognition Strengthens Global Development Strategy
The EMA Orphan Designation highlights the significant unmet medical need associated with LCA1 and XLRS, two rare inherited retinal diseases that can lead to severe vision impairment and blindness. According to Atsena Therapeutics, the designation provides valuable regulatory and commercial incentives designed to accelerate the development of therapies for rare diseases within Europe. Chief Executive Officer Patrick Ritschel stated that receiving orphan designation for both investigational therapies reinforces the importance of these programs as they advance toward pivotal development. He noted that the company is rapidly progressing enrollment in the Phase 3 LIGHTHOUSE trial evaluating ATSN-201, while preparations remain on schedule to launch the global Phase 3 trial of ATSN-101 later in 2026. In addition to the new EMA designation, both programs have previously received multiple regulatory incentives from the U.S. Food and Drug Administration (FDA), including Orphan Drug Designation, Fast Track Designation, Rare Pediatric Disease Designation, and Regenerative Medicine Advanced Therapy (RMAT) Designation, demonstrating broad regulatory support across major healthcare markets.
Pivotal Gene Therapy Programs Continue Advancing
ATSN-201 is an investigational gene therapy developed to treat X-linked Retinoschisis (XLRS) using Atsena’s proprietary AAV.SPR laterally spreading capsid technology, which is designed to efficiently deliver therapeutic genes to the central retina while reducing the surgical risks associated with traditional retinal gene therapy procedures. The ongoing LIGHTHOUSE trial has already entered its pivotal Phase 3 stage after encouraging Phase 1/2 clinical data demonstrated improvements in retinal structure, retinal sensitivity, best-corrected visual acuity, and low-luminance visual acuity, while maintaining a favorable safety profile with follow-up extending up to two years in some participants. The pivotal study plans to enroll approximately 76 patients aged six years and older, with microperimetry serving as the primary efficacy endpoint over a 52-week evaluation period. Meanwhile, ATSN-101, developed for GUCY2D-associated Leber Congenital Amaurosis Type 1 (LCA1), successfully completed its Phase 1/2 clinical trial, where patients receiving the high-dose treatment demonstrated durable clinically meaningful vision improvements through 36 months without treatment-related serious adverse events. Atsena is developing ATSN-101 through a strategic collaboration with Nippon Shinyaku Co., Ltd., which holds commercialization rights in the United States and Japan.
Advertisement
Gene Therapy Pipeline Targets Rare Inherited Blindness
Atsena Therapeutics continues expanding its position in the field of ocular gene therapy through a pipeline focused on inherited retinal diseases with limited or no available treatment options. Its proprietary AAV.SPR vector platform was engineered to improve delivery of therapeutic genes beyond the initial subretinal injection site, allowing efficient targeting of central retinal photoreceptors while minimizing surgical complications associated with foveal detachment. Preclinical studies have demonstrated broad retinal transgene expression and an encouraging safety profile compared with conventional AAV vectors. Beyond ATSN-101 and ATSN-201, the company’s research portfolio includes additional gene therapy candidates targeting Usher Syndrome Type 1B and Stargardt disease, reflecting its long-term strategy to address multiple causes of inherited blindness. With regulatory support from both the EMA and FDA, advancing pivotal clinical trials, and continued investment in innovative gene delivery technologies, Atsena Therapeutics is positioning itself to deliver next-generation genetic medicines capable of preserving and restoring vision for patients affected by rare retinal disorders.
Source: Atsena Therapeutics press release
